Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus METHYLPREDNISOLONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus METHYLPREDNISOLONE ACETATE.
BREO ELLIPTA vs METHYLPREDNISOLONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Methylprednisolone acetate is a synthetic glucocorticoid that binds to the glucocorticoid receptor, modulating gene expression to suppress inflammation, immune response, and adrenal function. It inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, and decreases cytokine production.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
40-80 mg intramuscular (IM) or intra-articular (IA) injection; for IM use, dose may be repeated every 1-4 weeks as needed. Maximum single IM dose: 120 mg.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Terminal half-life: 3-3.5 hours; correlates with duration of anti-inflammatory effect due to receptor-mediated action.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal: <10% unchanged; extensive hepatic metabolism to inactive metabolites primarily excreted renally as glucuronides and sulfates.
Category C
Category D/X
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid